获取途径

作者

Yating Wang Yasir Alsaraf Sai Samyuktha Bandaru Susan Lyons Leo Reap Tra Ngo Zhiyong Yu Qian Yu

作者单位

Hematology and Oncology，Ascension Providence Hospital，Southfield，MI，USA；Hematology and Oncology，Ascension Providence Hospital，Southfield，MI，USA；Hematology and Oncology，Ascension Providence Hospital，Southfield，MI，USA；Hematology and Oncology，Ascension Providence Hospital，Southfield，MI，USA；Hematology and Oncology，Ascension Providence Hospital，Southfield，MI，USA；Internal Medicine，Weiss Memorial Hospital，IL，USA；Breast Cancer Center，Shandong Cancer Hospital and Institute，Shandong First Medical University and Shandong Academy of Medical Sciences，Jinan，China；Department of Radiology，University of Chicago Medical Center，University of Chicago，Chicago，IL，USA

刊名

胃肠肿瘤学杂志

年份

2024

卷号

第15卷

期号

第4期

页码

1777-1788

关键词

Intrahepatic cholangiocarcinoma (iCCA) epidemiology survival trend

摘要

BackgroundIntrahepatic cholangiocarcinoma is a rare biliary tract cancer with increasing incidence and poor survival rates. This study aims to evaluate the incidence and survival trends of iCCA patients over 20 years using a national cancer database, and assess the temporal association between survival and landmark clinical trials.MethodsData was extracted from the Surveillance, Epidemiology, and End Results database. Age-adjusted incidence rates were calculated from 2000 to 2020. Overall sur...更多

BackgroundIntrahepatic cholangiocarcinoma is a rare biliary tract cancer with increasing incidence and poor survival rates. This study aims to evaluate the incidence and survival trends of iCCA patients over 20 years using a national cancer database, and assess the temporal association between survival and landmark clinical trials.MethodsData was extracted from the Surveillance, Epidemiology, and End Results database. Age-adjusted incidence rates were calculated from 2000 to 2020. Overall survival was analyzed based on diagnosis time and disease stage. Subgroup analysis was performed for patients diagnosed between 2015 and 2020. Landmark clinical trials were reviewed to determine temporal changes in survival.ResultsIn this analysis of 28,918 iCCA patients, the AAIR increased from 0.49 per 100,000 in 2000 to 1.38 in 2020 [annual percent change 6.94, 95% confidence interval : 6.32 to 7.56], with a notable decline from 2019 to 2020. Incidence rates overall displayed an uptrend course across subgroups divided by sex, race, age, and disease stage. The age-adjusted median overall survival improved from 5.28 months in 2000 to 9.3 months in 2013, then stabilized between 8.0–9.0 months after 2013. Using 2010 as a cutoff, when the ABC-02 trial was published, the decade-based mOS increased from 6.55 months in 2000–2010 to 9.06 months in 2010–2020. During 2015–2020, the overall mOS was 8.8 months, with mOS of 24.3, 12.1, and 5.4 months for local, regional, and distant stages, respectively.ConclusionsThe study indicates a steady rise in iCCA incidence since 2000 across all subgroups. Survival rates improved since 2000 but stabilized after 2013, following the ABC-02 trial publication in 2010. The impact of more recent clinical trials on survival rates requires further analysis in the coming years.收起

文献类型

期刊